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Abstract
Antibodies are quintessential affinity reagents for the investigation and determination of a protein’s expression patterns,
localization, quantitation, modifications, purification, and functional understanding. Antibodies are typically used in
techniques such as Western blot, immunohistochemistry (IHC), and enzyme-linked immunosorbent assays (ELISA), among
others. The methods employed to generate antibodies can have a profound impact on their success in any of these
applications. We raised antibodies against 10 serum proteins using 3 immunization methods: peptide antigens (3 per
protein), DNA prime/protein fragment-boost (‘‘DNA immunization’’; 3 per protein), and full length protein. Antibodies thus
generated were systematically evaluated using several different assay technologies (ELISA, IHC, and Western blot).
Antibodies raised against peptides worked predominantly in applications where the target protein was denatured (57%
success in Western blot, 66% success in immunohistochemistry), although 37% of the antibodies thus generated did not
work in any of these applications. In contrast, antibodies produced by DNA immunization performed well against both
denatured and native targets with a high level of success: 93% success in Western blots, 100% success in
immunohistochemistry, and 79% success in ELISA. Importantly, success in one assay method was not predictive of
success in another. Immunization with full length protein consistently yielded the best results; however, this method is not
typically available for new targets, due to the difficulty of generating full length protein. We conclude that DNA
immunization strategies which are not encumbered by the limitations of efficacy (peptides) or requirements for full length
proteins can be quite successful, particularly when multiple constructs for each protein are used.
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Introduction
The post-genomic era has ignited a growing demand for the
cost-effective generation of high quality, affinity-purified polyclon-
al reagents to support the routine detection and/or measurement
of numerous protein biomarkers in basic and applied research,
and as diagnostic tools. Antibody reagents support traditional
immunodetection tools such as immunoblotting, immunohisto-
chemical (IHC) analysis, immunoprecipitation, flow cytometry,
ELISA, as well as more advanced proteomic assay platforms such
as planar or bead-based antibody multiplexing microarrays and
antibody-oriented mass-spectrometry technologies [1–7]. In de-
signing immunization strategies for these immunodetection
methods, the epitope on the target protein that is recognized by
the antibody can exist in multiple conformations, ranging from
linear, as in a fully denatured protein, to conformationally
complex epitopes that are more rigidly structured and often
composed of several discontinuous regions, as displayed in folded
proteins [8].
The generation of antibody reagents to meet the demands of
proteomic applications continues to be driven by conventional
protein immunization approaches [9]. Classical protein immuni-
zation strategies most often rely on synthetic peptides [6,7,10,11],
large fragment or full-length recombinant proteins of bacterial
[9,12,13] or mammalian cell origin [6], or purified native proteins
[14] as sources of immunogens.
By virtue of their low cost, simplicity of synthesis, and historical
track-record for polyclonal and monoclonal antibody production
the use of peptides as immunogens is widespread [6,10,11,15,16].
Antibodies raised against peptides represent the majority of
antibodies available through antibody catalog vendors. Because
very small peptides are poorly immunogenic [14] and large ones
are challenging to synthesize, peptide fragments deployed as
immunogens typically consist of 12 to 20 amino acid residues
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constrain the utility of peptide immunizations. Among them are
challenges in antigen design based on issues such as lack of
effective algorithms for predicting surface regions in the absence of
protein structure information or B cell epitopes and [17–19].
Moreover, the conventionally used size of 12–20 residues rarely
encompasses more than a single epitope and is likely to lack
secondary and tertiary conformational structure [9,10].Conse-
quently, it is much less likely to generate antibodies capable of
binding natively folded protein [8] in a sandwich ELISA, although
they can work well in many applications against the protein in a
denatured form and have widespread proteomic applications.
Full length protein antigens address many of the limitations
attributed to peptides. Inherently, they contain surface regions,
multiple immunogenic epitopes, and are likely to fold to form (at
least partially) native structures even if synthesized in prokaryotic
systems [9]. However, recombinant synthesis and/or purification
of full length protein antigens can be a daunting task, takes
significant time and resources, and is encumbered by uncertainty
regarding successful production [20].
More innovative approaches such as DNA (or ‘‘genetic’’)
immunization have emerged as alternative and/or complementary
tools to classical antibody generation strategies. DNA immuniza-
tion employs an expression plasmid encoding the selected antigen
to immunize animals. The transfected tissues of the immunized
animal express the antigen which subsequently drives an antibody
response [21–25]. DNA immunization with sequences coding
polypeptide protein regions combines the advantages of both full
length protein and peptide and immunization approaches,
providing immunogens that comprise relatively large regions of
the target protein with the potential for multiple epitopes, faster
turn-around, and greater accessibility than full-length protein. We
chose a strategy of using DNA for priming, and using the protein
fragment encoded by the DNA-construct for boosting. It has been
consistently reported that this combination strategy results in
clearly superior antibody responses when compared to immuni-
zations using either DNA for both priming and boosting, or a
protein fragment for both priming and boosting. [26–28]. These
published reports are entirely in keeping with our own in-house
observations and experience.
Despite the widespread use of synthetic peptide antigens for
generating antibodies, no well controlled, quantitative, directly
comparative studies demonstrating their performance on multiple
targets relative to other antigens such as purified protein have been
published. Most reports deal with a single protein in a limited
number of applications. Many reports discuss the performance of
off-the-shelf reagents obtained from catalog vendors; however,
they generally relate anecdotal evidence and their interpretation is
often limited due to lack of information on study design controlling
for any of the many variables that influence antibody production
and immunoassay performance (antigen design, immunization
protocols, immunoassay variables) [29–33].
To better understand the strengths and weaknesses of different
immunization approaches we carried out a systematic study
comparing 3 immunization strategies, i.e., using peptides (Pep-
Abs), DNA (DNA-Abs; i.e. DNA prime/encoded polypeptide
boost), and full length protein (FLP-Abs) to generate antibodies
against 10 different serum proteins. These were selected based on
their commercial availability as high purity, native full length
proteins. These proteins are well established markers in clinical
medicine and the steps that led them there, including generation of
high quality antibodies, could serve as models for newly discovered
biomarkers. The polyclonal antibodies against these targets made
by the 3 immunization strategies were then stringently evaluated
for fitness of use against their target full-length protein in several
commonly used immunologic techniques, including those where
the protein exists in a relatively native state, such as ELISA, and
those in which the target protein exists in different states of
denaturation, such as Western blots and IHC.
Methods
Antigens
Proteins targeted in this study were transferrin (TF), thyroglob-
ulin (TG), thyroxine binding globulin (TBG), alpha-fetoprotein
(AFP), sex hormone binding globulin (SHBG), prostate specific
antigen (PSA), carcinoembryonic antigen (CEA), alpha-1-antitryp-
sin (AAT), alpha-2-macroglobulin (A2M), and prostatic acid
phosphatase (PAP). Proteins were obtained from SCIPAC
(Sittingboure, Kent, UK) and Lee Biosolutions (St. Louis, MO).
Purity was analyzed by SDS PAGE and was greater than 98% for
all proteins. All proteins were stored at 280 degrees C unless
otherwise recommended by the manufacturer.
Immunogen Design and Synthesis
For each of the 10 target proteins non-overlapping regions were
selected as peptide antigens. The peptides were designed and
synthesized by three leading suppliers; 21
st Century (Marlboro,
MA), Pi Proteomics (Huntsville, AL), and New England Peptide
(Gardner, MA). The peptide suppliers used their in house methods
to generate the designs and up to 3 designs were provided from
each company for each target, resulting in a total of 68 individual
peptide designs to the 10 targets. One non-overlapping design was
then selected from each company for each target, giving a total of
30 peptide designs. The 30 designs were selected from the pool of
68 designs using the following additional criteria: designs were
ranked based on surface accessibility (we argued that peptides
buried in the folded protein are unlikely to yield antibodies that
bind native, folded protein in a sandwich ELISA), the absence of
any post-translational modification (since the peptide immunogen
will not contain these), and lastly sequence identity to paralogs to
ensure that the antibodies are specific. Structural information was
available for most of the 10 targets and encompassed the regions
for 58 of the peptide designs. Upon review, 15 peptide designs
received for the 3 companies solicited were rejected due to lack of
surface accessibility in the structure, and 5 were rejected because
of identity to a paralog, or because they contained sites of post-
translational modification. The remaining peptides were ranked
by their identity to the host animal with the lowest identity selected
to avoid immune tolerance. The peptide lengths varied from 10 to
20 residues, with an average length of 16 residues. Peptides were
synthesized with a cysteine at either the N- or C-terminus of the
peptide to allow conjugation. Peptides were .85% pure and
conjugated to KLH using maleimide chemistry (Pierce, Rockford,
IL) for immunization.
Three DNA immunization antigens per target were designed
according to similar principles to those followed in the peptide
design, although regions were primarily selected to encompass an
entire domain, or a compact folded region. Domains were selected
based on Uniprot listed domain information. Structural informa-
tion was not available for 5 of the 30 designs. Surface accessibility
was not relevant for ranking since all encompassed large regions of
the protein, (80–152 residues, average 114), and thus all the
designs contained substantial surface exposed regions. Sequences
were ranked and selected based on lowest identity to the host
animal, lowest identity to paralogs, and avoidance of post-
translational modifications. Synthetic genes of the antigens were
synthesized (Integrated DNA Technology, Coralville, IA) and
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(Promega, Madison, WI) and an E. coli expression plasmid based
on pSP2b (Sigma, St. Louis,MO) with a Ptac-lac promoter. The
latter plasmid was used to produce the portion of the protein
encoded by the DNA construct for an antibody affinity
purification column and for a single protein fragment boost [26–
28] following DNA immunization to improve antibody yields. This
E.coli protein, containing a his tag, was produced in cultures
induced by ITPG, spun down, frozen, and lysed, Lysate was
solubilized in 7 M Guanidine and purified over HisPur Cobalt
resin (Thermo Fisher Scientific, Rockford, IL) using 250 mM
imidazole for elution. Sequence details of peptide and DNA
designs are shown in Figure 1.
Immunization
All animal work was approved prior to start by the SDIX
Institutional Animal Care and Use Committee and performed in a
USDA Registered (50-R-0013), AAALAC accredited (accredita-
tion number 001011) facility. In total 140 rabbits were used in this
study. Immunization regimes were consistent with well-established
industry protocols [34]. Two New Zealand white rabbits, 12 weeks
of age, weighing 5.5 to 6.5 lbs, were immunized with each of the
antigens (30 peptides, 30 DNA constructs, 10 full-length proteins).
KLH conjugated peptides (0.2 mg per rabbit) were administered
in complete Freund’s adjuvant (CFA) by subcutaneous injection of
4 different sites. At weeks 3, 5 and 7 animals were boosted with
0.2 mg of conjugated peptide in incomplete Freund’s adjuvant
(IFA) administered as described previously. Serum was collected
over a 3 day period 2 weeks after the final boost. The DNA
antigen constructs were conjugated to nano-gold particles and
administered via gene gun (Helios, Biorad, Hercules,CA) to the
inside of the ears (3 mg total) and boosted with DNA (gene gun) at
week 2 (3 ug). At week 5 animals were given a single boost of
100 mg of recombinant E. coli protein fragment derived from the
same gene fragment in CFA by subcutaneous injection of 4
different sites, and serum was collected at week 7. Full length
protein (250 mg per rabbit) was administered following the same
immunization routes and schedule as described for peptides.
Antibody Purification
To minimize the effect of animal-to-animal variability the sera
from each set of 2 rabbits were pooled for purification and
analysis. Sera from each treatment group were purified on their
respective immunogen . Pep-Abs were affinity-purified using the
cognate peptide used for immunization coupled via the N- or C-
terminal cysteine to sepharose [35]. DNA Abs were purified on
column resins to which we coupled the recombinant E. coli protein
fragment derived from the same sequence used for the DNA
immunization. FLP-Abs were were affinity purified on the
purified, full length serum proteins coupled to cyanogen-bromide
activated sepharose (GE, Piscataway, NJ). Antibodies were eluted
using 0.1 M glycine buffer, pH 2.5, neutralized immediately and
dialyzed against PBS for a total of 3 buffer exchanges. Purified
antibodies were quantified by absorbance at 280 nm. For
sandwich assays, antibodies were biotinylated using NHS-LC-
Biotin (Pierce, Rockford, IL).
Figure 1. Regions of proteins selected for peptide and DNA immunization designs. Each protein is represented in grey with the length in
amino acids of the monomeric unit indicated. 2 proteins, TG and A2M are too large to fit proportionally and gaps in the grey band are shown in areas
where no designs were selected. Designs selected for peptides are shown in red and designs for DNA shown in blue.
doi:10.1371/journal.pone.0028718.g001
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Direct bind ELISA was performed with purified full-length
antigen coated at a concentration of 1 ug/ml in 0.05 M carbonate
buffer pH 9.6 dispensed at 100 ml per well in 96-well microplates
(Nunc MaxiSorp, Nalge Nunc, Rochester, NY) [33]. Three-fold
serial dilutions of antisera were evaluated using standard protocols
and developed with goat-anti-rabbit IgG, Fc specific (Jackson
Immunochemicals, West Grove PA) secondary antibody and
tetramethylbenzidine/peroxide solution (TMB, Moss, Pasadena,
MD) as the color developing reagent. Plates were read after
15 minutes of development in a microtiter plate reader (Spec-
traMax, Molecular Devices, Sunnyvale, CA).
Sandwich ELISAs
Sandwich immunoassays were performed by coating purified
antibodies at a concentration of 2.5 ug/ml in 0.05 M carbonate
buffer pH 9.6, 100 ml per well onto 96 well microplates (0.25 mgo f
antibody per well). Four-fold serial dilutions of purified full-length
native antigen ranging from 100 ng/ml to 0.024 ng/ml were
added to the wells, followed by subsequent addition of biotinylated
purified antibody (0.5 ug/ml), and horseradish peroxidase labeled
streptavidin (0.2 ug/ml; Jackson Immunochemicals, West Grove,
PA). Color was developed as previously described. All antibodies
within a treatment group for a protein (such as all Pep-Abs to a
given target) were paired with each other, both as capture and
detection antibodies. Additionally, FLP-Abs were paired with
every Pep-Ab and DNA-Ab to that protein as both capture and
detection antibodies. This resulted in a total of 31 different
sandwich assays for each target.
Western Blot Analysis
The immunological reactivity of 69 antibodies (one DNA-Ab
was lost due to insufficient yield) derived from synthetic peptide,
full-length protein, and DNA-polypeptide immunizations was
characterized by Western blot analysis against denatured full-
length protein samples. Protein samples were electrophoretically
separated under denaturing conditions on SDS-PAGE, 4–20%
Tris-HCl pre-cast gels in a Criterion Cell apparatus (Bio-Rad,
Hercules, CA) in running buffer as recommended by the
manufacturer (Bio-Rad, Hercules, CA). Fractionated proteins
were electro-blotted onto nitrocellulose membranes (0.45 mm pore
size, Protran, Whatman, Germany) in a semi-dry electrophoretic
transfer cell unit (Trans-BlotH SD, Bio-Rad, CA) and then blocked
with TBST (Sigma, St.Louis, MO) supplemented with 2% Difco
skim milk (Becton Dickinson, Sparks, MD).
After an overnight incubation at 4–8uC, secondary antibody
(horseradish peroxidase-conjugated goat anti-rabbit, Invitrogen,
Carlsbad, CA) was added to each blot. Membrane blots were then
developed with chemiluminescent substrate (SuperSignalH West
Femto, Thermo Scientific, Rockford, IL) and the signal was
captured with a multi-purpose Image Station 440CF system (ver.
3.6, Eastman Kodak, NY). Each immunoblot was inspected
thoroughly for the presence of a band at the protein’s expected
molecular weight by adjusting brightness, contrast, and magnifi-
cation settings using the 1D Image Analysis software (Kodak, ver.
1.0).
Immunohistochemistry (IHC)
Immunohistochemical analysis on formalin-fixed, paraffin-
embedded human tissue specimens was carried out, for reasons
of cost and practicability, only using the antibodies raised against
CEA and PSA, and was performed by LifeSpan BioSciences
(Seattle, Washington). Following formalin-fixation, tissue speci-
mens were de-paraffinized in xylene and rehydrated sequentially
in a stepwise fashion with decreasing ethanol concentrations and a
final wash in water.
After probing with anti-CEA and anti-PSA unlabeled primary
antibody at dilutions ranging from 2.5 mg/ml to 20 mg/ml to allow
for optimization , immunoreactivity to target proteins was detected
with secondary biotinylated anti-rabbit IgG (Vector Laboratories,
Burlingame, CA) and avidin-biotin-alkaline phosphatase complex
(Vectastain ABC kit, Vector Laboratories, Burlingame, CA),
visualized with Vector Red chromogen (Vector Laboratories,
Burlingame, CA), and then counterstained with Harris hematox-
ylin (Richard Allan Scientific, Kalamazoo, MI). Stained slides
were imaged with a DVC1310C digital camera mounted on a
microscope (Nikon Eclipse E400, Nikon Instruments, Melville,
NY). The degree of staining was assessed by a single pathologist
blinded to the experimental variables of the study. Each antibody
was then ranked on a scale of 1 to 7 where a rank of 1 was the
highest-ranking performance in IHC using 3 criteria: specific
staining of target tissues; least number of cells stained; and
differential staining between target and control tissues.
Data Analysis
Two-way analysis of variance (ANOVA) and a Welsh’s t-test
were computed for comparisons of means of antisera titers,
antibody yields, antibody specific activities (defined as the amount
of antibody required to produce a signal intensity of 0.5
absorbance units in direct bind ELISA), and for homologous
and heterologous sandwich assay performance for antibodies
generated by the 3 immunization strategies.
Odds ratios and their 95%confidence intervals (CI) were
calculated for Western blot data and analyzed by Fisher’s Exact
Test using GraphPad Prism 5 (ver. 5.04; GraphPad Software, La
Jolla, CA).
Results
Antibodies were evaluated based on yield after affinity
purification, specific activity of the purified antibody, and the
ability of these antibodies to work in sandwich ELISAs, Western
blots, and IHC. Affinity purification of the antibodies, each on the
antigen used for immunization (in the case of the DNA-
immunization group, the protein fragment encoded by the
respective DNA sequence), allowed assays to be normalized and
compared based on mass of antibody rather than just serum titer.
Furthermore, the sandwich assays required the use of purified
antibody for both the capture phase as well as for labeling as a
detector. Thirty antibodies made to peptides (Pep-Abs), 29
antibodies made to polypeptides by DNA immunization (DNA-
Abs; a very low yield occurred for 1 of the 30 immunizations) and
10 antibodies made to full length protein (FLP-Abs) were
evaluated. These represented sera from 140 rabbits, two rabbits
per treatment group.
Yields of antibodies after affinity purification varied widely
(Figure 2). Purified antibody yields from FLP-Ab (mean for 10
proteins of 36.9 mg from 80 ml of antisera, standard deviation
616.0 mg) were significantly higher (P,0.01) than yields using
other immunization methods (Table 1). While there was high
variability from protein to protein, Pep-Abs (geometric mean of
3.7 mg from 80 ml of sera) had significantly greater (P,0.01)
yields than DNA-Abs (geometric mean of 0.8 mg).
In direct bind ELISAs (Figure 3), 7 of 10 DNA-Abs showed
better specific activity than the respective Pep-Abs. In 7 instances
(AFP, TBG, SHBG, PSA, CEA, AAT, PAP) one of the 3 DNA-
Abs performed close to the value yielded by the respective FLP-
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protein show a performance similar to that of respective FLP-Abs.
Overall, specific activities of Pep-Abs were significantly lower
(P,0.01) than those of DNA-Abs (Table 1).
In sandwich ELISAs, DNA-Abs were more sensitive (lower limit
of detection) than Pep-Abs, but were less sensitive than FLP-Abs
(Figure 4). In sandwich assays paired with FLP-Abs, DNA-Abs
showed significantly higher (P,0.01) sensitivity than Pep-Abs
(Table 1). Both Pep-Abs and DNA-Abs did not achieve the
sensitivity of assays configured solely with FLP-Abs.
In a number of instances, it was possible to configure a
sandwich assay with 2 DNA-Abs raised against the same target,
and more rarely with a single DNA-Ab (self-sandwich),
suggesting multiple epitopes recognized by the polyclonal
antisera. Ten, 6, and 4 of the 29 DNA-Abs could be paired to
produce assays with sensitivities of at least 1 nM, 100 pM, and
10 pM, respectively. In contrast, no Pep-Ab was capable of
producing a sandwich assay of 1 nM sensitivity with another
Pep-Ab raised against the same protein. As would be expected
due to the nature of a single epitope, no Pep-Ab would pair with
itself (self-sandwich).
Western blot analysis
A total of 69 antibodies generated by three immunization
strategies were tested for immuno-reactivity against full length
SDS-denatured protein by Western blot analysis (Table 2). Of the
29 DNA-Abs, 26 (90%) and 27 (93%) recognized the denatured
protein at either the 100 ng/ml or 1000 ng/ml antibody probing
concentration, respectively. Only 14 of 30 (47%) and 17 of 30
(57%) Pep-Abs were immuno-reactive at either concentration
while all FLP-Abs performed well. Overall, the likelihood of
observing an immuno-reactive antibody for Western blot applica-
tions was significantly greater for DNA-Abs than for Pep-Abs, as
indicated by odds ratios for DNA-Abs vs. Pep-Abs of 9.9 (95% CI
2.5 to 39.9) and 10.3 (95% CI 2.1 to 51.5) for the lower and higher
antibody probing concentrations tested, respectively (P,0.01). A
10-fold increase in the antibody probing concentration yielded
positive Western blot results for 3 additional Pep-Abs and 1
Figure 2. Yields of purified antibody following affinity
purification from 80 ml of pooled rabbit sera. Each symbol
represents the yield for each pool of 2 rabbits. There are 3 constructs
per protein for each of the DNA-Ab and Pep-Ab methods and a single
data point for the pool from full length native immunization (FLP-Abs).
doi:10.1371/journal.pone.0028718.g002
Table 1. The overall effect of the various immunization strategies across ten different selected serum proteins on antibody yield,
antisera titer, antibody specific activity, and assay sensitivity of different antibody combinations by ELISA.
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1Geometric mean of assay sensitivity reported for homologous (self) and heterologous antibody combinations against native, and ‘‘within’’ immunization method.
2Geometric mean of antibody yield for a 80-ml antiserum affinity purification run.
3Geometric mean of antisera titers was intrapolated from a titration curve at 0.500 absorbance.
doi:10.1371/journal.pone.0028718.t001
Figure 3. Specific activity of purified antibodies in direct bind
ELISA to full length antigen. All purified antibodies were titered
against full length antigen in direct bind ELISA. Data was processed
with a four parameter curve fit (XLfit, IDBS, Guildford, UK) and expressed
as the quantity of purified antibody required to give an absorbance of
0.5 at 650 nm using a TMB substrate. Lower amounts of antibody
required (shown on an inverted scale) are indicative of higher specific
activity). Each symbol represents the activity for each pool of 2 rabbits.
There are 3 constructs per protein for each of the DNA-Ab and Pep-Ab
methods and a single data point for the pool from full length native
immunization (FLP-Abs).
doi:10.1371/journal.pone.0028718.g003
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concentration.
Immunohistochemistry (IHC)
Independent of immunization strategy, all seven anti-CEA
polyclonal antibodies were considered of excellent quality for use
in IHC applications showing superb staining of multiple benign
colonic epithelium and colon carcinoma specimens (Figure 5). All
antibodies were titered to optimal concentration in all IHC studies
described here and results discussed are at the optimal concen-
trations. To differentiate among antibodies in the setting of this
overall high performance, ranking of antibodies was primarily
based on the extent of variable staining in cell types of other tissues
rather than presence and/or intensity of staining of the
carcinomas. For instance, the highest-ranked antibody, R01736,
a DNA-Ab, showed outstanding staining of colon carcinoma and
colonic epithelium, moderate staining of sweat ducts (known to
express CEA [4]) and neutrophils, but showed no staining of other
normal tissues known not to express CEA, such as skin (dermis and
epidermis), prostate glands and stroma, colon muscularis propria,
and skeletal muscle tissues (Figure 5). In contrast, the lowest-
ranked anti-CEA antibody D3305-20, a Pep-Ab, showed prom-
inent nonselective staining in ganglion cells and peripheral nerves
of the prostate and colon.
Five of 7 anti-PSA antibodies were characterized as highly
successful for use in IHC showing excellent staining of prostatic
epithelium and carcinoma. The highest-ranked anti-PSA anti-
body, R01733, was a DNA-Ab. Staining of prostate epithelium
and carcinoma and differential staining of positive and negative
cell types was excellent and accompanied by very little background
staining (Figure 6). Staining of other tissues (skin epidermis and
dermis, prostate stroma, colonic mucosa and smooth muscle,
skeletal myocytes) was virtually nonexistent. In contrast, two Pep-
Abs, D3305-17 and D3305-18, performed poorly in IHC. D3305-
17 yielded relatively weak staining of prostatic epithelium and
cancer, unimpressive differential staining of prostate in compar-
ison with other tissues, and non-specific nuclear staining of some
cell types including colon epithelium and skin (data not shown).
D3305-18 showed predominantly nuclear staining in most tissues
with weak to moderate positivity in colonic epithelium, smooth
muscle, skin epidermis, and skeletal muscle and overall poor
discrimination between positive and negative cell types (Figure 6).
Overall success in multiple applications
Not all antibodies that worked in one application necessarily
worked in other applications. Table 3 provides the cumulative
success rates for each group of antibodies (Pep-Abs, DNA-Abs,
FLP-Abs) across different applications. As expected, a greater
fraction of Pep-Abs performed only in one application usually with
a denatured target as in Western blot or IHC or in no application
at all, while DNA-Abs performed more often in multiple
applications, demonstrating higher versatility. The best perfor-
mance under this paradigm was observed for FLP-Abs.
Discussion
Despite decades of refining algorithms for optimal antigen
design [18,19,36–38] the use of peptide immunization continues
to suffer from poor predictability and modest overall success at
generating antibodies that recognize native folded proteins,
whereas success at recognizing denatured proteins can be high
[15]. The performance of peptide immunization has heretofore
not been compared to other approaches in a carefully designed
and controlled, systematic and comprehensive study. The current
investigation provides such a systematic analysis of the perfor-
mance of 3 different immunization strategies, applied to 10
representative, well-characterized targets, and evaluates the
respective performance of the resultant antibodies across a range
of relevant assay applications. While all Pep-Abs demonstrated
strong reactivity with the immunizing peptide, and while yield of
affinity-purified Pep-Abs (using immobilized peptide) was accept-
able, we found that 37% of Pep-Abs in this study did not perform
adequately in any of the commonly used immunologic methods
tested. The performance of Pep-Abs was poorest in sandwich
ELISAs with native full length protein. Only 7 of 30 antibodies
were capable of pairing with an antibody to full length protein to
Figure 4. Sensitivity of antibodies in sandwich ELISA when
paired with an antibody to full length protein. Standard curves
were processed with four parameter curve fitting software and
sensitivity expressed as the amount of antigen that could be detected
at an OD 650 nm of 0.1 absorbance units above background. Each
symbol represents the sensitivity for each pool of 2 rabbits. There are 3
constructs per protein for each of the DNA-Ab and Pep-Ab methods
and a single data point for the pool from full length native
immunization (FLP-Abs).
doi:10.1371/journal.pone.0028718.g004
Table 2. Western blot analysis: frequency of antibodies
elicited by DNA immunization methodology or via peptide
and full-length protein (native) immunizations that
recognized the corresponding full length protein target run
under SDS-PAGE denaturing conditions.
Primary Antibody Concentration (ng/ml)
Protein DNA - Abs Pep-Abs FLP-Abs
100 1000 100 1000 100
A2M 3/3 3/3 2/3 3/3 1/1
AAT 3/3 3/3 2/3 2/3 1/1
CEA 3/3 3.3 1/3 1/3 1/1
PSA 3/3 3/3 1/3 1/3 1/1
AFP 3/3 3/3 1/3 2/3 1/1
PAP 2/3 3/3 1/3 2/3 1/1
TBG 3/3 3/3 1/3 1/3 1/1
TF 3/3 3/3 3/3 3/3 1/1
TG 0/2 0/2 1/3 1/3 1/1
SHBG 3/3 3/3 1/3 1/3 1/1
Totals: 26/29 27/29 14/30 17/30 10/10
(89.6%) (93.1%) (46.6%) (56.6%) (100.0%)
doi:10.1371/journal.pone.0028718.t002
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demonstrated sensitivities of less than 100 pM. Pep-Abs demon-
strated significantly better performance under denaturing condi-
tions, i.e. in Western blots or IHC. At the higher concentration of
probing antibody, 57% of the Pep-Abs were able to recognize the
target protein in Western blots. The performance of peptide
immunizations to produce affinity reagents capable of recogniz-
ing the cognate target relative to the other immunization
strategies is in agreement with the rates of 25% to 50% for
peptide fragments (12 to 15 residues in length) [16] and 56% (7
to 20 residues) in another studies [15] for monoclonal and
polyclonal antibodies, respectively.
Even optimally designed peptides are unlikely to assume the
conformational structure of the respective residues as present in
the context of a full-length native, non-denatured protein. Pep-Abs
are therefore expected to perform better in assays where the target
protein is at least partially denatured. It is important to note that
the denaturing conditions to which a protein is subjected may
differ between applications, e.g. Western blotting and IHC, and
that performance in one assays format may not necessarily be
predictive of performance in another. Thus, 2 of the anti-CEA
Pep-Abs performed well in IHC but failed to perform in Western
blots under the conditions employed in this study (Figure 7),
whereas no such differences were observed with anti-PSA Pep-Abs
(Figure S1). Western blots for DNA-Abs and Pep-Abs for other
proteins are shown in in Figures S2, S3, S4, S5, S6, S7, S8, S9.
Pep-Abs showed lower specific activity in direct-bind ELISA to
native full length protein compared to DNA-Abs or FLP-Abs. It is
possible that the rotational flexibility of peptide antigens leads to
the induction and purification of multiple antibody species that
Figure 5. Immunohistochemical staining of human colon carcinoma and normal tissue specimens for carcinoembryonic antigen
(CEA). Staining was performed with highest rank antibody R10736 and lowest rank D3305-20 generated by DNA and peptide immunization,
respectively. DNA-Ab R01736 was generated against the sequence encoding amino acids 410–500. Pep-Ab D3305-20 was made from a peptide of
amino acids 561–570. After full optimization both of these antibodies were found to work best at 2.5 mg/ml, the level shown here. Magnification
ranges from 206to 406.
doi:10.1371/journal.pone.0028718.g005
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PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28718Figure 6. Immunohistochemical staining of human prostate carcinoma normal tissue specimens for prostate specific antigen (PSA).
Staining was performed with the highest rank antibody R10733 (2.5 mg/ml) generated by DNA immunization and the lowest rank peptide-antibody
D3305-18 (10 mg/ml). DNA-Ab R01733 was generated against the sequence encoding amino acids 37–139. Pep-Ab D3305-18 was made from a
peptide of amino acids 126–144. Antibodies are shown at their optimized concentration, 2.5 mg/ml for R10733 and 10 mg/ml for D3305-18.
Magnification ranges from 206to 406.
doi:10.1371/journal.pone.0028718.g006
Table 3. Effect of immunization method on fitness for purpose of resultant antibodies in a number of immunologic techniques.
Immunization method
Method Pep-Abs DNA-Abs FLP-Abs
Western blot only 12/30 (40%) 3/29 (10%) 0/10 (0%)
IHC only 2/6 (33%) 1/6 (17%) 0/10 (0%)
Western blot/IHC only 1/6 (17%) 0/29 (0%) 0/10 (0%)
Sandwich ELISA only 1/30 (3%) 1/29 (3%) 0/10 (0%)
Western blot and sandwich ELISA ,1 nM sensitivity 5/30 (17%) 22/29 (76%) 10/10 (100%)
Western blot and sandwich ELISA ,100 pM sensitivity 1/30 (3%) 13/29 (49%) 10/10 (100%)
Western blot and sandwich ELISA ,10 pM sensitivity 0/30 (0%) 5/29 (17%) 9/10 (90%)
Western blot and sandwich ELISA and IHC 1/6 (17%) 6/6 (1005) 6/6 (100%)
No performance in any application (i.e., complete failure) 11/30 (37%) 1/29 (3%) 0/10 (0%)
doi:10.1371/journal.pone.0028718.t003
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native target, thus accounting for low specific activity of affinity-
purified polyclonal peptide antibody.
During the course of this study, we encountered issues that may
further impact the success of commercial Pep-Abs. We observed
that 26% of peptide designs provided by the peptide suppliers were
predicted to be buried within the native protein’s structure and
therefore predicted not to be suitable for developing antibodies
that recognize native structures (although such designs may well
work in denaturing applications). In 9% of the designs additional
issues such as high sequence identity to a paralog, presence of
internal cysteine residues (that would interfere with conjugation),
presence of an N-linked glycosylation site, and even deletion of an
amino acid were noted that would have negatively impacted
antibody performance. Thus, more than a third of the original
peptide designs were a priori judged as not suitable for developing
antibodies and were rejected, highlighting the importance of
critical review of antigen design when ordering a custom Pep-Ab.
It stands to reason to wonder, therefore, that in situations where
the end-user has no control over peptide design (such as when
ordering a premade antibody from a catalogue) suboptimal
immunogen design may be of particular concern. It is possible
that selecting peptide designs based on surface exposure may have
introduced some bias into the success rates of the antibodies in
Western blots. Peptide design is a critical variable in determining
success for antibodies to recognize folded proteins. Algorithms for
predicting ‘antigenicity’ and B-cell epitopes generally perform
poorly [17] and not all post-translational modifications are
annotated. Because of the small size of peptides, appropriate
regions must be selected very carefully to ensure localization on
the surface of the folded protein as well as absence of interfering
post-translational modifications. We found little consensus among
the three leading suppliers of peptides regarding designs, with only
14 of the 68 initial designs overlapping another company’s design,
and only 2 of the designs with complete consensus overlapped
provided by all three suppliers. Furthermore, there were no
statistically significant differences in the resulting antibody
performance between the 3 companies (data not shown).
Antibodies produced by DNA-encoded polypeptide immuniza-
tion draw on the advantage of being raised against a larger fraction
of the protein, may potentially recognize several epitopes that are
also present on the surface of the native protein, and are therefore
expected to more likely react with the protein target in its correct,
native conformational structure than antibodies raised using
peptide antigens. The substantially higher specific activities
observed for DNA-Abs compared to Pep-Abs are consistent with
this argument, as are the considerably higher success rates in
sandwich ELISAs where the antigens are analyzed under more
physiologic, non-denaturing, conditions. Similarly, it would be
expected that full length protein would encompass all the possible
epitopes. Twenty-two of 29 DNA-Abs performed well in both
Western blots and sandwich ELISA, and 14 of these achieved
sensitivities of less than 100 pM in ELISAs using FLP-Ab as the
second partner. One antibody worked in ELISA, but not Western
blot, possibly indicative of highly conformation-specific properties.
Only 3 of 29 antibodies worked exclusively in Western blot, but no
other applications. All 6 antibodies tested in IHC showed
acceptable sensitivity and tissue specificity. Only 1 DNA-Ab failed
to demonstrate utility in any of the applications tested. Taken
together these results suggest that the polyclonal DNA-Abs to
larger polypeptide antigens contain antibodies to both linear and
conformation-dependent epitopes. It is interesting to speculate
whether even better results could be obtained by immunizing with
a DNA construct that encompasses the entire target protein;
however, the size of many of the proteins in this study, ranging
from 30 kD to a 720 kD tetramer precluded the reliable use of the
full length DNA; and production of the protein for boosting in E
coli would prove very challenging.
Success rates across antigen strategies varied among protein
targets used in the study, and it proved important to have used
more than one antigen design per target. Using 3 antigen designs,
we observed a 100%, 80%, and 40% chance of at least 1 of these
yielding a DNA-Ab that performed in a sandwich ELISA (paired
with the respective FLP-Ab) at a sensitivity of 1 nM, 100 pM, and
10 pM, respectively. Analogous likelihoods observed for Pep-Abs
were 40%, 10%, and 0%, respectively (Figure 8). Success rates
using not an FLP-Ab/DNA-Ab pair, but a DNA-Ab/DNA-Ab
pair (typically two different DNA-Abs to the same target) in
sandwich ELISAs (as might often be necessary for a new
biomarker where no full length protein or FLP-Abs exist), were
40%, 30%, 20%, at sensitivities of 1 nM, 100 pM, and 10 pM,
respectively. Pep-Ab/Pep-Ab-paired sandwich assays were uni-
formly unsuccessful at all sensitivities even when 2 different Pep-
Abs to the same target were used. Similarly, for Western Blot
applications, only an immunization strategy employing 3 different
peptide designs ensured the recovery of at least one useful Pep-Ab
for all 10 targets, even though the selected target proteins are all
well established as highly immunogenic and non-challenging with
Figure 7. Western blot analysis of full-length carcinoembryonic antigen (CEA) run under denaturing conditions. Each immunoblot
was probed with DNA (DNA-Abs) derived anti-CEA antibodies or peptide-derived (Pep-Abs) antibodies at 100 ng/ml and 1:4000 anti-rabbit HRP. Lane
1=molecular weight standards (kDa); Lane 2 and 3=10 ng and 1 ng of CEA per lane, respectively. DNA-Abs R01736, R01737, and R01738 were
generated against the sequences encoding amino acids 410–500, 588–686, and 317–421 respectively. Pep-Abs D3305-19, D3305-20,and D3305-21
were made from peptides of amino acids 616–630, 561–570, and 321–339 respectively.
doi:10.1371/journal.pone.0028718.g007
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Ab antigen design would have been required for 9 of 10 target
proteins given that in these 9 targets all 3 selected DNA antigens
yielded DNA-Abs successful in Western blots. Only for a single
protein, TG did all three of the DNA-encoded polypeptide designs
fail to generate any antibody compatible with Western blot
applications at any of the assay conditions tested in this study.
Despite the success rate of one DNA construct design per protein
within this limited sample set we recommend that multiple
constructs be employed to maximize the probability of obtaining
antibodies with the desired assay performance characteristics. This
is certainly critical in the event of developing immunoreagents to
protein biomarker targets that are immunologically more
demanding than the targets addressed in the present study, and/
or if antibodies with a broader scope of assay applications are
intended.
It is noteworthy, that all 6 DNA-Abs tested in IHC showed
excellent performance in this application. We accept that our
inferences regarding the success rate in IHC applications are
limited by the small number of protein targets and respective
antibodies evaluated in this study. However, despite the restricted
data set, the current observations confirm our previous findings
and those of others that DNA-Abs perform in IHC at a level
equivalent to their protein counterparts [2].
A current limitation of the DNA-based immunization approach
described here relates to using a protein fragment generated in E.
coli both for a final boost and for affinity purification. While DNA
immunization has been shown to be very effective at priming
immune responses, a single protein boost is recognized to often
dramatically increase titers and is commonly practiced as a
‘‘prime-boost’’ protocol for producing antibodies [26–28]. Al-
though antibody yields with this technique still appear low in
comparison to Pep-Abs, their binding characteristics more than
counterbalance this, thus providing higher yields if regarded from
the viewpoint of specific activity. Since a prokaryotic protein is
used for affinity purification, this approach would not be expected
to result in purification of antibodies that recognize post-
translationally modified forms of the protein, or conformational
epitopes dependent on disulfide bonds. Whereas such antibodies
may indeed have been generated by DNA immunization, they
would have been lost during the purification step. Efforts are
underway to refine the DNA immunization method by employing
eukaryotically expressed protein fragments for both protein boost
and in the affinity purification step. It is noteworthy, however, that
use of the prokaryotic protein portion for affinity purification
frequently gave rise to repertoires of antibodies that recognized
denatured as well as native conformations (as evidenced by
sandwich ELISA with native protein).
Immunizations with full length protein produced higher
polyclonal antibody titers, greater yields, and superior perfor-
mance in sandwich ELISA compared to other immunization
strategies studies. These antibodies also performed well in Western
blot and IHC, with a 100% success rate. The full length proteins
used in this study are well-characterized serum proteins, many of
which have been extensively studied for in-vitro diagnostic
applications, and are highly immunogenic, consistent with this
success rate. Their performance is likely also related to the fact that
one would expect the most diverse repertoire of surface-epitope-
specific antibody species with this approach.
As pointed out, immunization with full length protein is
generally fraught with a number of challenges related to difficulties
that may be encountered in gene construction, expression, and
purification. For multiple application uses DNA-encoded poly-
peptide immunization may offer an effective alternative with
significantly higher probabilities of success than peptide-based
immunization approaches. It remains important, still, to use more
than one antigen design for a given target to achieve a high
probability of success for any one desired application.
An important trend in the last decade has been the development
of proteome-scale studies enabling a deeper understanding of
biology and a much wider search for biomarkers. The increased
scale of these whole proteome-screening technologies makes the
generation of high quality affinity reagents an ever-more urgent
need, as these reagents are a mainstay of quantitative biological
measurements. Ironically, the technology for generating what
continues to be the gold standard affinity reagents, animal-
Figure 8. Success rates in sandwich ELISA using 3 different immunization designs for Pep-Abs or DNA-Abs. 8a) Success is defined as
the percent of the time that at least one of the designs will give rise to an antibody that can pair with an FLP-Ab to the target giving sensitivity at or
above the indicated concentrations. 8b) Success when at least one of the designs will form a sandwich pair with itself or with another antibody within
the group (Pep-Abs with Pep-Abs, DNA-Abs with DNA Abs) to give sensitivity at or above the indicated concentrations.
doi:10.1371/journal.pone.0028718.g008
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sound understanding of the attributes of antibodies generated by
different approaches, and advances in the generation of such
reagents applicable in proteome-wide analytical methodology will
allow the field to move forward successfully. Whereas it is always
critical to test antibodies in their ultimate intended application to
optimize chances of success, the present study demonstrates that
DNA immunization-based technology can generate antibodies
that have a relatively high success rate in multiple immunoassay
formats and avoid many of the limitations of Pep-Abs as well as of
the challenges of FLP-Abs, thus representing a technology that can
augment the arsenal of methods to fill the needs of proteomic-scale
investigations. Our current study was limited to interrogate these
aspects with regard to well characterized and highly immunogenic
targets; additional work will be required to characterize the
performance of this technology in comparison with others with
regard to less immunogenic targets.
Supporting Information
Figure S1 Western blot analysis of full-length prostate
specific antigen (PSA) run under denaturing conditions.
Each immunoblot was probed with DNA (DNA-Abs) derived anti-
PSA antibodies or peptide-derived (Pep-Abs) antibodies at
100 ng/ml and 1:4000 anti-rabbit HRP. Lane 1=molecular
weight standards (kDa); Lane 2 and 3=10 ng and 1 ng of PSA per
lane, respectively.
(TIF)
Figure S2 Western blot analysis of full-length prostatic
acid phosphatase (PAP) run under denaturing condi-
tions. Each immunoblot was probed with DNA (DNA-Abs)
derived anti-PAP antibodies or peptide-derived (Pep-Abs) anti-
bodies at 100 ng/ml and 1:4000 anti-rabbit HRP. Lane
1=molecular weight standards (kDa); Lane 2 and 3=10 ng and
1 ng of PAP per lane, respectively.
(TIF)
Figure S3 Western blot analysis of full-length thyroxine
binding globulin (TBG) run under denaturing condi-
tions. Each immunoblot was probed with DNA (DNA-Abs)
derived anti-TBG antibodies or peptide-derived (Pep-Abs) anti-
bodies at 100 ng/ml and 1:4000 anti-rabbit HRP. Lane
1=molecular weight standards (kDa); Lane 2 and 3=10 ng and
1 ng of TBG per lane, respectively.
(TIF)
Figure S4 Western blot analysis of full-length transfer-
ring (TF) run under denaturing conditions. Each immu-
noblot was probed with DNA (DNA-Abs) derived anti-TF
antibodies or peptide-derived (Pep-Abs) antibodies at 100 ng/ml
and 1:4000 anti-rabbit HRP. Lane 1=molecular weight standards
(kDa); Lane 2 and 3=10 ng and 1 ng of TF per lane, respectively.
(TIF)
Figure S5 Western blot analysis of full-length thyro-
globulin (TG) run under denaturing conditions. Each
immunoblot was probed with DNA (DNA-Abs) derived anti-TG
antibodies or peptide-derived (Pep-Abs) antibodies at 100 ng/ml
and 1:4000 anti-rabbit HRP. Lane 1=molecular weight standards
(kDa); Lane 2 and 3=10 ng and 1 ng of TG per lane, respectively.
(TIF)
Figure S6 Western blot analysis of full-length alpha-1-
antitrypsin (AAT) run under denaturing conditions. Each
immunoblot was probed with DNA (DNA-Abs) derived anti-AAT
antibodies or peptide-derived (Pep-Abs) antibodies at 100 ng/ml
and 1:4000 anti-rabbit HRP. Lane 1=molecular weight standards
(kDa); Lane 2 and 3=10 ng and 1 ng of AAT per lane,
respectively.
(TIF)
Figure S7 Western blot analysis of full-length alpha-
fetoprotein (AFP) run under denaturing conditions. Each
immunoblot was probed with DNA (DNA-Abs) derived anti-AFP
antibodies or peptide-derived (Pep-Abs) antibodies at 100 ng/ml
and 1:4000 anti-rabbit HRP. Lane 1=molecular weight standards
(kDa); Lane 2 and 3=10 ng and 1 ng of AFP per lane,
respectively.
(TIF)
Figure S8 Western blot analysis of full-length alpha-2-
macroglobulin (A2M) run under denaturing conditions.
Each immunoblot was probed with DNA (DNA-Abs) derived anti-
A2M antibodies or peptide-derived (Pep-Abs) antibodies at
100 ng/ml and 1:4000 anti-rabbit HRP. Lane 1=molecular
weight standards (kDa); Lane 2 and 3=10 ng and 1 ng of A2M
per lane, respectively.
(TIF)
Figure S9 Western blot analysis of full-length sex
hormone binding globulin (SHBG) run under denaturing
conditions. Each immunoblot was probed with DNA (DNA-
Abs) derived anti-SHBG antibodies or peptide-derived (Pep-Abs)
antibodies at 100 ng/ml and 1:4000 anti-rabbit HRP. Lane
1=molecular weight standards (kDa); Lane 2 and 3=10 ng and
1 ng of SHBG per lane, respectively.
(TIF)
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